PF
PFSA.US Profusa, Inc. Common Stock
- Market cap
- USD 271K
- P/E
- 0.0x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PFSA.US undervalued?
Graham numberThe Graham number of Profusa, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Profusa, Inc. Common Stock fundamental analysis
No fundamental analysis for Profusa, Inc. Common Stock yet.
Profusa, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Profusa, Inc. Common Stock
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, …
Full company profileProfusa, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Profusa, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -11.7M | -11.1M | -6.07M | -4.50M | -13.2M | -13.1M |
| EBITDA | -5.05M | -13.2M | -6.00M | -4.81M | -30.7M | -11.8M |
| Net Income | -10.3M | -20.2M | -10.3M | -9.23M | -35.8M | -24.4M |
| EPS | -32 | -63 | -77 | -357 | -107 | -423 |
| Balance Sheet | ||||||
| Total Assets | 11.4M | 1.03M | 1.89M | 3.07M | 3.78M | 1.04M |
| Total Liabilities | 95.0M | 101M | 112M | 122M | 30.4M | 28.2M |
| Shareholders' Equity | -83.7M | -99.8M | -110M | -119M | -26.7M | -27.1M |
| Cash & Short-term Investments | 856K | 78.0K | 142K | 191K | 1.78M | 719K |
| Total Debt | 24.0M | 31.0M | 40.4M | 48.2M | 14.8M | 14.0M |
| Cash Flow | ||||||
| Operating Cash Flow | -10.7M | -7.70M | -4.40M | -2.07M | -16.2M | -10.4M |
| Capital Expenditure | 0.00 | 0.00 | 2.00K | 0.00 | 8.00K | 156K |
| Free Cash Flow | -10.7M | -7.70M | -4.40M | -2.07M | -16.3M | -10.6M |
| Ratios | ||||||
| ROA | -90.7% | -1,960.9% | -543.1% | -300.4% | -949.0% | -2,343.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
Profusa, Inc. Common Stock dividends
Profusa, Inc. Common Stock has not paid dividends in the last 5 fiscal years.
Last stock split: 1:4 on Aug 17, 2026.
Who owns Profusa, Inc. Common Stock
- Insiders 49.96%
- Institutions 3.37%
- Public & others 46.67%
- Shares outstanding 606K
- Free float 518K
Top funds holding PFSA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| GAMCO Intl SICAV Merger Arbtrg I (USD) | 169.00 | 0.00% | 0.00% | Jun 2026 |
Top institutions holding PFSA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Geode Capital Management, LLC | 16.4K | 0.03% | -46.56% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.94K | 0.01% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 3.76K | 0.01% | +109.99% | Jun 2026 |
| IFP Advisors, LLC | 3.00K | 0.01% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.60K | 0.00% | 0.00% | Jun 2026 |
| FMR Inc | 500.00 | 0.00% | +3,746.15% | Jun 2026 |
| SBI Securities Co Ltd | 404.00 | 0.00% | +797.78% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
Profusa, Inc. Common Stock company profile
- Company name
- Profusa, Inc. Common Stock
- Ticker
- PFSA.US
- Exchange
- USA Stocks
- Listed since
- Jul 11, 2025
- Sector
- Healthcare
- Industry
- Health Care Technology
- Fiscal year end
- December
- Address
- 626 Bancroft Way, Berkeley, CA, United States, 94710
- Phone
- 925 997 6925
- Website
- profusa.com
About Profusa, Inc. Common Stock
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Profusa, Inc. Common Stock management
6- Dr. Chung-Bin Hwang Ph.D.President · born 1968
- Mr. Fred S. KnechtelChief Financial Officer · born 1961
- Mr. Jack E. Stover CPACEO & Executive Chairman · born 1953
- Mr. William McMillanCo-founder, Chief Scientific Officer & Head of Research · born 1951
- Mr. David IckeHead of Digital Health Business
- Mr. Sean GivensHead of Government Business